Literature DB >> 16566448

Comprehensive characterization of the 293-ORF6 cell line.

B T Butman1, A Lizonova, D E Brough, J M Sowers, R Sheets, J Gall, P Newton, P Gomez.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16566448

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN： 1424-6074


× No keyword cloud information.
  8 in total

1.  Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials.

Authors:  Richard A Koup; Laurie Lamoreaux; David Zarkowsky; Robert T Bailer; C Richter King; Jason G D Gall; Douglas E Brough; Barney S Graham; Mario Roederer
Journal:  J Virol       Date:  2009-04-01       Impact factor: 5.103

2.  Epitope specificity delimits the functional capabilities of vaccine-induced CD8 T cell populations.

Authors:  Brenna J Hill; Patricia A Darrah; Zachary Ende; David R Ambrozak; Kylie M Quinn; Sam Darko; Emma Gostick; Linda Wooldridge; Hugo A van den Berg; Vanessa Venturi; Martin Larsen; Miles P Davenport; Robert A Seder; David A Price; Daniel C Douek
Journal:  J Immunol       Date:  2014-10-27       Impact factor: 5.422

3.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

Authors:  Andrew T Catanzaro; Richard A Koup; Mario Roederer; Robert T Bailer; Mary E Enama; Zoe Moodie; Lin Gu; Julie E Martin; Laura Novik; Bimal K Chakrabarti; Bryan T Butman; Jason G D Gall; C Richter King; Charla A Andrews; Rebecca Sheets; Phillip L Gomez; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2006-11-08       Impact factor: 5.226

4.  Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Authors:  Richard A Koup; Mario Roederer; Laurie Lamoreaux; Jennifer Fischer; Laura Novik; Martha C Nason; Brenda D Larkin; Mary E Enama; Julie E Ledgerwood; Robert T Bailer; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

5.  Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret.

Authors:  Srinivas S Rao; Wing-Pui Kong; Chih-Jen Wei; Neal Van Hoeven; J Patrick Gorres; Martha Nason; Hanne Andersen; Terrence M Tumpey; Gary J Nabel
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

6.  Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).

Authors:  Laurence Peiperl; Cecilia Morgan; Zoe Moodie; Hongli Li; Nina Russell; Barney S Graham; Georgia D Tomaras; Stephen C De Rosa; M Juliana McElrath
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

7.  Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications.

Authors:  Kazuhiro Ueyama; Keisuke Mori; Takuhei Shoji; Hidekazu Omata; Peter L Gehlbach; Douglas E Brough; Lisa L Wei; Shin Yoneya
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

8.  Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.

Authors:  Melissa M Hamilton; Gordon A Byrnes; Jason G Gall; Douglas E Brough; C Richter King; Lisa L Wei
Journal:  Mol Vis       Date:  2008-12-30       Impact factor: 2.367
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.